In the high-stakes world of biopharmaceutical manufacturing, the transition from clinical-scale development to commercial-grade production is often where life-saving innovations falter. For the Contract Development and Manufacturing Organization (CDMO) giant FUJIFILM Biotechnologies, the solution to this "valley of death" is not just more steel and concrete, but a radical rethinking of operational autonomy.
At the center of this transformation is Maja Herold Pedersen, who ascended to the role of Chief Operating Officer (COO) in September 2025. Pedersen, whose career trajectory has bridged the gap between quality assurance and operational leadership, is currently overseeing one of the most ambitious industrial expansions in the history of the pharmaceutical sector. With approximately $7 billion in capital projects currently underway across the United States, Europe, and the UK, FUJIFILM is positioning itself as the backbone of the next generation of global medicine.
The Global Expansion: A Multi-Billion Dollar Footprint
FUJIFILM Biotechnologies is currently executing a strategy of aggressive capacity growth designed to meet the surging demand for biologics and advanced therapies.
Key Infrastructure Milestones:
- Holly Springs, North Carolina: The crown jewel of the company’s US footprint, this $3.2 billion facility brought its first phase online in September 2025. A second phase, designed to double down on commercial-scale cell culture, is projected to come online by 2028.
- Hillerød, Denmark: The company is significantly scaling its Danish campus, adding eight 20,000-liter bioreactors and two additional downstream processing streams, cementing its status as a critical node in the European supply chain.
- Teesside, UK: In early 2026, the company unveiled what is currently the UK’s largest single-use CDMO facility, signaling a major commitment to flexible, agile manufacturing.
- Madison, Wisconsin: Subsidiary FUJIFILM Cellular Dynamics completed a $200 million expansion in May 2026, quadrupling its capacity for induced pluripotent stem cell (iPSC) manufacturing.
These investments are tied together by the "kojoX" model—a strategic framework that leverages standardized equipment, uniform quality systems, and consistent processes across all sites. The term, derived from the Japanese kojo (improvement and factory) and the "X" for exponential scale, aims to ensure that a drug substance process validated in one geography can be seamlessly transferred to another, drastically reducing regulatory friction and tech-transfer timelines.
From Quality to Operations: A Strategic Pivot
Maja Herold Pedersen’s leadership style is defined by her unique background. Before moving into the COO chair, she served as the company’s Chief Quality Officer (CQO). In a sector often paralyzed by the tension between production speed and regulatory compliance, Pedersen argues that the two are not in opposition.
"I’ve never been a quality-function-only leader," Pedersen notes. "I’ve always looked at the whole picture of how we get medicine to patients. It doesn’t matter whether I’m wearing a quality hat or some other hat; we need to make this work for patients in the end."
Her transition to COO was a deliberate choice by CEO Lars Petersen, who sought to institutionalize a "quality-first" mentality within the core of operations. By embedding the rigorous oversight of a quality officer into the operational mandate, the company is attempting to automate compliance, turning quality control from a gatekeeper into an enabler of efficiency.
Industrializing AI: The "Genki" Ecosystem
The most striking aspect of Pedersen’s current mandate is the aggressive deployment of Artificial Intelligence. Rather than relying on sporadic, isolated pilots, Pedersen has pushed for an integrated, company-wide AI ecosystem.
The "Genki" Framework
The centerpiece of this effort is "Genki"—an internal, secure, large language model (LLM) tailored for the nuances of biomanufacturing. Named after the Japanese concept of health and enthusiasm, Genki is designed to function within the company’s internal security umbrella.
"We knew that if we didn’t build it, people would start using public tools anyway," Pedersen explains. "So, rather than sit and wait, I had it built under our own roof."
Current AI Applications:
- Deviation Management: The system currently assists Subject Matter Experts (SMEs) in writing deviations, offering coaching based on historical norms and helping identify root causes by analyzing large datasets rather than relying on standard, pre-populated templates.
- Tech-Transfer Automation: The team is currently building agents capable of ingesting product data, organizing it into the required regulatory sequences, and automating documentation workflows.
- Human-in-the-Loop Scaling: Pedersen advocates for a "bottom-up" approach to AI. She envisions a future where employees are trained to code their own simple agents, creating a vast funnel of innovation. Only those agents that pass rigorous verification are promoted to the enterprise level for GMP (Good Manufacturing Practice) decision-making.
The Philosophy of Autonomy: The 9 People Fundamentals
Beyond technology, the cultural shift at FUJIFILM is guided by the "9 People Fundamentals." This framework is designed to empower individual decision-making, reducing the bureaucratic lag that often slows down global manufacturing operations.
"If we look at it like an organism," Pedersen explains, "we have our brain, but we also have numerous cells that work very well individually. If we bog people down in hierarchy, we lose that energy. The goal is to set people free to make the decisions they are best placed to make."
This empowerment comes with a caveat: accountability. Through a program titled "Leaders for Life," the company is retraining its leadership cohort to manage not by command and control, but by facilitating an environment where employees are accountable for the consequences of their autonomous decisions.
Implications for the Industry
The work being done at FUJIFILM Biotechnologies represents a significant shift in the CDMO landscape. By prioritizing "agentic" AI—tools that don’t just assist but perform tasks—and coupling it with a decentralized leadership culture, the company is challenging the industry’s status quo.
Future Outlook
- Regulatory Evolution: As the company pushes for the use of AI in GMP-regulated tasks, it will likely serve as a test case for how regulators view the validation of autonomous software in manufacturing.
- Operational Agility: The kojoX model, combined with high-capacity facilities, positions FUJIFILM to respond to market volatility—such as sudden shifts in demand for specific biologics—faster than competitors locked into rigid, site-specific processes.
- The Talent Paradigm: By focusing on the "9 People Fundamentals," the company is positioning itself as a modern workplace, which is crucial for attracting the specialized engineering and data-science talent required to maintain such a technologically advanced network.
For Maja Herold Pedersen, the end goal remains constant. Whether it is a multi-billion-dollar facility in North Carolina or an AI-driven deviation-management tool in Denmark, the focus is strictly on the patient. By "setting tools free" and "empowering the individual," FUJIFILM is attempting to prove that the path to faster, more reliable medicine is paved by a combination of massive industrial scale and radical digital autonomy.
As the company moves toward the next phase of its global buildout, the industry will be watching to see if this marriage of high-capital infrastructure and agile software-driven management can successfully set a new standard for the global biopharmaceutical supply chain.
About the Author
